Tag: performance

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Paul Miller Rejoins Grocery Outlet as Chief Purchasing and Merchandising Officer
Ian Ferry Promoted to Chief Financial Officer
Company Affirms Second Quarter and Fiscal 2026 Outlook

Net sales increased 22.5% year-over-year to $107.1 million

Jiangsu, China, June 09, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (Nasdaq: MTEN) (the “Company”) today announced that it has entered into a securities purchase agreement with certain institutional investors for the sale of up to 1,131,004 Class A ordinary shares, par value $0.00005 per share (“Class A Ordinary Shares”), at a purchase price of $2.00 per share, and pre-funded warrants to purchase Class A Ordinary Shares at an original exercise price of $2.00, with $1.99995 of the original exercise price pre-funded at the closing, and a remaining exercise price of $0.00005 per Class A Ordinary Share.

Inland Empire and High Desert Probate and Trust Real Estate Specialist Ranks in the Top 1% of California Realtors